Recruiting
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
NCT07748208· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
NCT07416552· Phase 1· Hoffmann-La Roche· Source
Recruiting
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
NCT07660055· Phase 1· Novartis Pharmaceuticals· Source
Contact: Marlene Bridwell
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841· Phase 1· Compass Therapeutics· Source
Contact: Ashley Servais
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479· Phase 1/2· Molecular Partners AG· Source
Contact: Research Director
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413· Phase 1· IDEAYA Biosciences· Source
Contact: Lindsey Becker, Primary Study Coordinator
Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT07189871· Phase 1/2· Radiopharm Theranostics, Ltd· Source
Contact: Marlene Bidwell
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726· Phase 1/2· Terremoto Biosciences Inc.· Source
Contact: Ashley Servais Degenhardt
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257· Phase 1/2· Tasca Therapeutics· Source
Contact: Ashley Servais
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Contact: Relay Therapeutics, Inc
Active, not recruiting
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· Phase 3· Amgen· Source
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277· Phase 3· Novartis Pharmaceuticals· Source
Contact: Marlene Bridwell
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591· Phase 1/2· Tango Therapeutics, Inc.· Source
Contact: Joel Michalski, MD, PhD (principal investigator)
Recruiting
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177· Phase 2· Endevica Bio· Source
Contact: Joel Michalski, MD, PhD
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756· Phase 1/2· Perspective Therapeutics· Source
Contact: Hanna Kurz
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033· Phase 2· Hoffmann-La Roche· Source
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670· Phase 2/3· Novartis Pharmaceuticals· Source
Contact: Marlene Bridwell
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636· Phase 1/2· Pathos AI, Inc.· Source
Contact: Evan Roberts
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Contact: Ying Li
Active, not recruiting
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501· Phase 2· BeOne Medicines· Source
Active, not recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499· Phase 1· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
NCT06524375· Phase 2· Genentech, Inc.· Source
Active, not recruiting
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217· Phase 1· Novartis Pharmaceuticals· Source
Recruiting
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
NCT06046495· Phase 1· Avistone Biotechnology Co., Ltd.· Source
Contact: Study Director, MD
Recruiting
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT06115135· Phase 2· Oncotherapeutics· Source
Contact: Ashley Servais, MPH
Active, not recruiting
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036· Phase 3· Amgen· Source
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062· Phase 1/2· Revolution Medicines, Inc.· Source
Contact: Ashley Servais
Active, not recruiting
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596· Phase 2· BicycleTx Limited· Source
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612· Phase 3· BriaCell Therapeutics Corporation· Source
Contact: Heather Cordes, CCRC
Recruiting
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
NCT05636618· Phase 1/2· Perspective Therapeutics· Source
Contact: Scott Degenhardt, NMAA
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941· Phase 4· Novartis Pharmaceuticals· Source
Contact: Ralph Hauke (principal investigator)
Recruiting
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312· Phase 1/2· Perspective Therapeutics· Source
Contact: Marlene Bridwell
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Recruiting
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114· Tempus AI· Source
Contact: Kimberly Wendt
Recruiting
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177· Tempus AI· Source
Contact: Brenda Broekemeier
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Active, not recruiting
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395· Phase 3· Tolmar Inc.· Source
Active, not recruiting
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766· Phase 1/2· Inhibrx Biosciences, Inc· Source
Contact: Lindsey Becker
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597· Phase 1/2· CellCentric Ltd.· Source
Contact: Ashley Servais
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
NCT03574571· Phase 3· Memorial Sloan Kettering Cancer Center· Source
Active, not recruiting
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT03436485· Phase 1/2· Orion Corporation, Orion Pharma· Source
Active, not recruiting
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
NCT03241186· Phase 2· Robert R. McWilliams, MD· Source
Active, not recruiting
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861· Phase 3· Eisai Inc.· Source